https://oncoinnovations.com/ https://oncoinnovations.com/corporate https://oncoinnovations.com/our-research https://oncoinnovations.com/investors https://oncoinnovations.com/news https://oncoinnovations.com/media https://oncoinnovations.com/contact-us https://oncoinnovations.com/legal https://oncoinnovations.com/governance-and-charters https://oncoinnovations.com/corporate-directory https://oncoinnovations.com/news/onco-innovations-announces-closing-of-private-placementt https://oncoinnovations.com/news/onco-innovations-announces-amendment-to-private-placement-pricing https://oncoinnovations.com/news/onco-innovations-announces-filing-of-preliminary-base-shelf-prospectus https://oncoinnovations.com/news/vancouver-canada-%E2%80%93-january-23-2026-%E2%80%93-onco-innovations-limited-(cboe-ca-onco)-(frankfurt-w1h-wkn-a3eksz)(otcqb-onnvf)-(-onco-or-the-company https://oncoinnovations.com/news/onco-innovations-engages-i2i-marketing-group-engagement-for-market-awareness-services https://oncoinnovations.com/news/onco-innovations-chairs-colorectal-cancer-canada-precision-oncology-forum-generating-roadmaps-for-the-next-era-of-cancer-care https://oncoinnovations.com/news/onco-innovations-engages-investment-bank-to-pursue-nasdaq-cross-listing-and-potential-concurrent-equity-offering https://oncoinnovations.com/news/onco-innovations-advances-optimization-and-scale-up-of-its-pnkp-inhibitor-technology-with-dalton-pharma-services-to-support-future-phase-1-clinical-studies https://oncoinnovations.com/news/onco-innovations-advances-ai-and-quantum-drug-discovery-with-kuano-collaboration-to-accelerate-pnkp-inhibitor-technology-development https://oncoinnovations.com/news/onco-innovations-inka-health-publishes-framework-on-transportability-of-real-world-evidence-and-use-in-health-technology-assessment https://oncoinnovations.com/news/onco-innovations-provides-shareholder-update-following-cboe-canada-investor-spotlight-focus-on-u-s-strategy https://oncoinnovations.com/news/onco-innovations-appoints-jared-rushton-to-board-of-directors https://oncoinnovations.com/news/vancouver-canada-october-27-2025-onco-innovations-limited-(cboe-ca-onco)-(frankfurt-w1h-wkn-a3eksz)(otcqb-onnvf)-(-onco-or-the-company-)-is-pleased-to-announce-that-it-has-closed-its-previously-announced-(see-news-release-dated-october-14-2025)-non-brokered-private-placement https://oncoinnovations.com/news/vancouver-canada-october-14-2025-onco-innovations-limited-(cboe-ca-onco)-(frankfurt-w1h-wkn-a3eksz)(otcqb-onnvf)-(-onco-or-the-company-)-announces-that-it-intends-to-complete-a-non-brokered-private-placement-(the-private-placement-)-of-up-to-1-428-572-units-of-the-company-(the-units-)-at-a-price-of-1-40-per-unit-for-aggregate-gross-proceeds-of-up-to-2-000-000-each-unit-shall-consist-of-one-common-share-(each-a-share-)-and-one-half-of-one-common-share-purchase-warrant-(each-whole-warrant-a-warrant-)-with-each-warrant-entitling-the-holder-to-purchase-one-share-at-an-exercise-price-of-2-00-for-a-period-of-thirty-six-(36)-months-the-company-also-intends-to-issue-shares-equal-to-1-0-of-the-total-of-shares-issued-in-the-private-placement-(the-admin-fee-shares-)-to-an-arm-s-length-third-party-as-an-administrative-fee-for-their-assistance-with-the-private-placement-in-connection-with-the-private-placement-the-company-may-pay-finders-fees-and-or-issue-finders-warrants-on-the-same-terms-as-the-warrants-to-eligible-parties-who-have-assisted-by-introducing-subscribers-to-the-private-placement-closing-of-the-private-placement-is-subject-to-certain-conditions-including-but-not-limited-to-the-receipt-of-all-necessary-regulatory-and-other-approvals-all-securities-issued-pursuant-to-private-placement-will-be-subject-to-a-hold-period-of-four-months-and-one-day-pursuant-to-applicable-securities-laws-the-company-intends-to-use-the-proceeds-of-the-private-placement-for-general-corporate-and-working-capital-purposes-including-in-pursuit-of-the-company-s-operational-and-research-and-development-objectives-and-for-investor-relations-purposes-the-securities-described-herein-have-not-been-and-will-not-be-registered-under-the-united-states-securities-act-of-1933-as-amended-or-any-u-s-state-securities-laws-and-may-not-be-offered-or-sold-in-the-united-states-absent-registration-or-available-exemptions-from-such-registration-requirements-this-press-release-does-not-constitute-an-offer-to-sell-or-a-solicitation-of-an-offer-to-buy-any-securities-in-the-united-states-or-in-any-jurisdiction-in-which-such-offer-solicitation-or-sale-would-be-unlawful-the-company-also-announces-the-appointment-of-mr-christopher-gulka-as-a-member-of-the-board-of-directors-effective-immediately-mr-gulka-brings-over-30-years-of-experience-in-capital-and-public-markets-he-founded-working-capital-corporation-a-corporate-finance-firm-specializing-in-valuations-due-diligence-and-management-consulting-he-previously-served-as-cfo-and-director-of-inner-spirit-holdings-ltd-and-has-held-senior-financial-and-board-roles-with-several-public-companies-across-the-mining-energy-cannabis-and-industrial-sectors-he-holds-a-bachelor-of-commerce-(with-distinction)-from-the-university-of-alberta-and-is-both-a-chartered-financial-analyst-(cfa)-and-chartered-professional-accountant-(cpa)-mr-gulka-succeeds-mr-graydon-bensler-on-the-board-the-company-thanks-mr-bensler-for-his-valuable-contributions-and-dedicated-service-about-onco-innovations-limited-onco-innovations-is-a-canadian-based-company-dedicated-to-cancer-research-and-treatment-specializing-in-oncology-onco-s-mission-is-to-pursue-the-prevention-and-treatment-of-cancer-through-pioneering-research-and-innovative-solutions-the-company-has-secured-an-exclusive-worldwide-license-to-patented-technology-that-targets-solid-tumours-on-behalf-of-onco-innovations-limited-thomas-o-shaughnessy-chief-executive-officer-for-more-information-please-contact-thomas-o-shaughnessy-chief-executive-officer-tel-1-888-261-8055-investors-oncoinnovations-com-the-cse-has-not-reviewed-and-does-not-accept-responsibility-for-the-accuracy-or-adequacy-of-this-release-forward-looking-statements-caution-this-news-release-contains-forward-looking-statements-including-in-relation-to-the-private-placement-generally-and-the-anticipated-use-of-funds-and-closing-date-thereof-as-well-as-to-the-company-s-business-and-plans-generally-and-other-statements-that-are-not-historical-facts-forward-looking-statements-are-often-identified-by-terms-such-as-will-may-potential-should-anticipate-expects-and-similar-expressions-all-statements-other-than-statements-of-historical-fact-included-in-this-release-are-forward-looking-statements-that-involve-risks-and-uncertainties-there-can-be-no-assurance-that-such-statements-will-prove-to-be-accurate-and-actual-results-and-future-events-could-differ-materially-from-those-anticipated-in-such-statements-important-factors-that-could-cause-actual-results-to-differ-materially-from-the-company-s-expectations-include-the-failure-to-complete-the-private-placement-as-contemplated-or-at-all-that-the-anticipated-proceeds-may-be-lower-than-expected-the-failure-to-receive-regulatory-approval-in-respect-of-the-private-placement-and-other-risks-detailed-from-time-to-time-in-the-filings-made-by-the-company-with-securities-regulators-the-reader-is-cautioned-that-assumptions-used-in-the-preparation-of-any-forward-looking-information-may-prove-to-be-incorrect-events-or-circumstances-may-cause-actual-results-to-differ-materially-from-those-predicted-as-a-result-of-numerous-known-and-unknown-risks-uncertainties-and-other-factors-many-of-which-are-beyond-the-control-of-the-company-the-reader-is-cautioned-not-to-place-undue-reliance-on-any-forward-looking-information-such-information-although-considered-reasonable-by-management-at-the-time-of-preparation-may-prove-to-be-incorrect-and-actual-results-may-differ-materially-from-those-anticipated-forward-looking-statements-contained-in-this-news-release-are-expressly-qualified-by-this-cautionary-statement-the-forward-looking-statements-contained-in-this-news-release-are-made-as-of-the-date-of-this-news-release-and-the-company-will-update-or-revise-publicly-any-of-the-included-forward-looking-statements-as-expressly-required-by-applicable-law https://oncoinnovations.com/news/onco-innovations-advances-preclinical-program-as-nucro-technics-begins-analytical-development-for-pnkp-technology https://oncoinnovations.com/news/onco-innovations-appoints-dr-michael-lock-to-scientific-clinical-advisory-board https://oncoinnovations.com/news/onco-innovations-commences-activities-to-manufacture-nanoparticle-formulation-with-dalton-pharma-to-supply-preclinical-animal-studies https://oncoinnovations.com/news/onco-innovations-to-chair-colorectal-cancer-canada-precision-oncology-forum-driving-the-future-of-cancer-care https://oncoinnovations.com/news/onco-innovations-appoints-dr-john-mackey-to-scientific-clinical-advisory-board https://oncoinnovations.com/news/onco-innovations-announces-90-of-0-60-warrants-have-been-exercised https://oncoinnovations.com/news/vancouver-canada-august-13-2025-onco-innovations-limited-(cboe-ca-onco)-(frankfurt-w1h-wkn-a3eksz)(otcqb-onnvf)-(-onco-or-the-company-)-is https://oncoinnovations.com/news/onco-innovations-advances-progress-towards-first-in-human-trial-with-avance-clinical-start-up-agreement https://oncoinnovations.com/news/inka-health-selected-by-onemednet-to-lead-ai-driven-oncology-project-using-real-world-data-for-external-control-arms https://oncoinnovations.com/news/onco-innovations-announces-private-placement https://oncoinnovations.com/news/onco-innovations-appoints-dr-dennis-hall-to-scientific-clinical-advisory-board https://oncoinnovations.com/news/onco-innovations-signs-agreement-with-redwood-ai-to-advance-discovery-and-evaluation-of-its-pnkp-inhibitor-technology https://oncoinnovations.com/news/onco-innovations-strengthens-clinical-leadership-with-appointment-of-dr-islam-mohamed-as-advisory-board-chair https://oncoinnovations.com/news/onco-innovations-enters-agreement-with-nucro-technics-for-ind-enabling-studies-taking-a-key-step-toward-human-trials https://oncoinnovations.com/news/onco-innovations-ceo-highlights-strategic-milestones-and-r-d-progress-in-special-investors-conference-call https://oncoinnovations.com/news/onco-innovations-welcomes-astrazeneca-s-interest-in-founding-role-in-promai-an-inka-led-ai-oncology-consortium https://oncoinnovations.com/news/onco-innovations-ceo-to-host-special-investors-conference-call-on-wednesday-july-2-2025 https://oncoinnovations.com/news/inka-health-co-founders-publish-new-study-advancing-real-world-applicability-of-lung-cancer-clinical-trial-outcomes https://oncoinnovations.com/news/onco-innovations-engages-the-university-of-alberta-and-cross-cancer-institute-to-expand-pnkp-inhibitor-research-into-hard-to-treat-cancers https://oncoinnovations.com/news/onco-innovations-inka-health-to-launch-global-ai-oncology-consortium-to-advance-predictive-cancer-research https://oncoinnovations.com/news/onco-innovations-announces-start-of-manufacturing-of-preclinical-testing-material-for-its-pnkp-inhibitor-technology-by-dalton-pharma https://oncoinnovations.com/news/onco-innovations-extends-marketing-program https://oncoinnovations.com/news/onco-innovations-announces-appointment-of-professor-steven-jones-as-senior-scientific-advisor-strengthening-technical-acumen-in-ai-powered-precision-oncology https://oncoinnovations.com/news/onco-innovations-celebrates-listing-of-common-shares-on-cboe-canada https://oncoinnovations.com/news/onco-innovations-announces-closing-of-private-placement https://oncoinnovations.com/news/onco-innovations-licensed-pnkp-inhibitor-technology-shown-to-increase-sensitivity-of-cancer-cells-to-radiation-in-animal-study https://oncoinnovations.com/news/onco-innovations-announces-expression-of-interest-between-inka-health-and-global-data-leader-quantify-research https://oncoinnovations.com/news/onco-innovations-applauds-lundin-cancer-fund-for-4-million-contribution-to-the-canadian-cancer-society